Fibroblast Growth Factor Receptor 1 (FGFR1, Basic fibroblast growth factor receptor 1, BFGFR, bFGF-R, CD331, CEK, c-fgr, FGFBR, FGFR-1, FLG, FLJ99988, FLT2, Fms-like tyrosine kinase 2, H2, H3, H4, H5, HBGFR, KAL2, N-SAM, OGD)

FGFR1 (fibroblast growth factor receptor 1) is a member of the fibroblast growth factor receptor family containing an Ig-like domain and a tyrosine kinase domain. This receptor has multiple isoforms and is a Type I membrane protein. FGFR1 is a widely expressed membrane receptor, with distinct isoforms expressed in specific tissues. FGFR1 binds fibroblast growth factor and induces mitogenesis and cellular differentiation. Defects in FGFR1 result in Pfeiffer syndrome associated with craniosynostosis. FGFR1 can be modified by phosphorylation and can bind basic/acidic fibroblast factor depending on the receptor isoform. FGFR1 has been shown to interact with N-cadherin and NCAM. Fibroblast growth factors (FGFs) are members of a large family of structurally related polypeptides (17-38kD) that are potent physiological regulators of growth and differentiation of a wide variety of cells of mesodermal, ectodermal and endodermal origin. FGFs are substantially involved in normal development, wound healing and repair, angiogenesis, a variety of neurotrophic activities, in hematopoiesis as well as in tissue remodeling and maintenance. They also have been implicated in pathological conditions such as tumorigenesis and metastasis. To date, the FGF family consists of at least 23 members designated FGF1 through FGF23. Four genes encoding for high affinity cell surface FGF receptors (FGFRs) have been identified: FGFR1 [flg-1(fms-like gene 1)]; FGFR2 [bek (bacterial expressed kinase gene product)]; FGFR3 (cek-2), and FGFR4. Multiple additional variants (isoforms) arising by alternative splicing have been reported: soluble, secreted, or possibly cleaved forms of FGFR1 and FGFR2 have also been found in body fluids or were artificially constructed, [e.g. a soluble FGF-binding protein containing the extracellular region of FGFR1 and the secreted form of placental alkaline phosphatase (FRAP1)]. FGFRs are members of the tyrosine kinase family of growth factor receptors. They are glycosylated 110- 150kD proteins that are constructed of an extracellular ligand binding region with either two (alpha type) or typically three (alpha type) immunoglbulin (Ig)-like domains and an eight amino acid acidic box, a transmembrane region, and a cytoplasmic split tyrosine kinase domain that is activated following ligand binding and receptor dimerization. The ligand binding site of FGFRs is confined to the extracellular Ig-like domains 2 and 3. FGFRs exhibit overlapping recognition and redundant specificity. One receptor type may bind with a similar affinity several of the FGFs. Also one FGF type may bind similarly to several distinct receptors. This accounts for the rather identical effects of different FGF ligands on common cell types. FGF?s binding to cellular FGFRs depend on or is markedly facilitated by the low-affinity interaction of FGF with the polysaccharide component of the cell surface or extracellular matrix heparan sulfate proteoglycans (HSPG). For example, perlecan, a basement membrane HSPG, promotes high affinity binding of FGF2 in vitro and angiogenesis in vivo. Signal transduction by FGFRs requires dimerization or oligomerization and autophosphorylation of the receptors through their tyrosine kinase domain. Subsequent association with cytoplasmic signaling molecules leads to DNA synthesis or differentiation. The signaling and biological responses elicited by distinct FGFRs substantially differ and are dictated by the intracellular domain. At the mRNA level, FGFR1 is highly expressed in developing human tissues including the brain (preferentially in neurons), vascular basement membranes, skin, and bone growth plates. It may be found in most anchorage dependent cells on their membrane and also may be localized around and in nuclei. Pfeiffer syndrome, as well as other disorders of human skeletal development, is the result of a mutation in the extracellular domain of FGFR1. Applications: Suitable for use in ELISA and Western Blot. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4 degrees C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot Store at -20 degrees C. Aliquots are stable for at least 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.